Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2006
The general aim is to evaluate the antiviral activity and safety of increasing doses of oral administered RTV-boosted BILR 355 BS (75 mg and 150 mg twice daily) in HIV-1-infected, NNRTI-experienced patients, followed by 28 day combination therapy with Tipranavir or Lopinavir based HAART-regimen
Epistemonikos ID: 86808cf434f2c98942c891fc3a250ea8d6484820
First added on: Dec 01, 2021